Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Use of parapheny for maldehyde-O-beta-D-allose pyranoside for treating neurogenic pain

A technology of allopyranoside and p-benzaldehyde, which is applied in drug combination, nervous system diseases, and pharmaceutical formulations, etc.

Active Publication Date: 2008-09-03
KUNMING BAKER NORTON PHARMA
View PDF1 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In the prior art, people have found through research that tofu glucoside has sedative, hypnotic and analgesic effects, and it has been clinically used to relieve headaches, dizziness and sleep disorders of neurosis, but in the prior art There is no report on the use of tofu glucoside for the treatment of neuropathic pain diseases

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of parapheny for maldehyde-O-beta-D-allose pyranoside for treating neurogenic pain
  • Use of parapheny for maldehyde-O-beta-D-allose pyranoside for treating neurogenic pain
  • Use of parapheny for maldehyde-O-beta-D-allose pyranoside for treating neurogenic pain

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0043] 1. Animal models of neurogenic pain

[0044] Hot plate, tail flick, and writhing are commonly used animal models for screening classic acute pain analgesics, but they are not suitable for screening neuropathic pain drugs. In recent years, the establishment and development of animal models of neurogenic pain have greatly promoted the research on the mechanism of action and drugs of neurogenic pain.

[0045] According to the pathogenesis of neurogenic pain, laboratories often use injured peripheral nerves or central nervous system to create animal models, Bennett GJ in 1988 [1] The sciatic nerve chronic compression injury model (referred to as the CCI model) was established, which was widely accepted soon because of its relatively simple operation and reliable results. Although more animal models have been found [2～3] , but the CCI model is still the main model for evaluating the efficacy of neuropathic pain in drug development. Clinically effective treatments for neur...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to the use of the compound of helicid, or its pharmaceutically acceptable salts, esters or solvates, for the manufacture of medicaments in treating neuropathic pain.

Description

field of invention [0001] The invention relates to the field of medicinal chemistry, in particular, the invention relates to a new application of p-benzaldehyde-O-β-D-alopyranoside compound. Background of the invention [0002] According to the duration of pain, clinically, pain can be divided into two types: acute pain and chronic pain. The mechanisms of these two types of pain are essentially different. Acute pain is called nociceptive pain, that is, pain caused by tissue trauma. With the repair of tissue trauma, the pain stops naturally. Analgesics (such as narcotic analgesics and non-steroidal antipyretic analgesics) can be used during the attack period Chronic pain is mainly neurogenic pain, its pathogenesis is extremely complex, and it is difficult to treat. It is a new field of basic and clinical research and drug development of pain medicine. It has been developed for about 30 years abroad, and has a research history of about 10-15 years in China. [0003] 1. Basic...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/7034A61P25/04A61K31/7048
CPCA61K31/7048A61P25/04
Inventor 王壮胡利昆罗质璞李云峰杨红菊赵楠王子厚王滟华张利生
Owner KUNMING BAKER NORTON PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com